Category: Jurisdictions
-
Warner Bros. Discovery “pulls a Samsung” against Nokia with U.S. FRAND/antitrust claims after similar ones in other venues; also argues exhaustion by Apple, Amazon licenses
in the midst of a major merger battle, Warner Bros. Discovery is pursuing FRAND matters in at least three different venues now.
-
Federal Circuit holds there is no uniform deadline for appeal of ITC ruling if some defendants were found to violate, others weren’t
Crocs thought it had more time because of the Presidential review period. The Federal Circuit disagreed.
-
Bayer adds to COVID patent wars: sues Pfizer/BioNTech, Moderna, J&J over mRNA technology
Bayer’s Monsanto has sued Pfizer/BioNTech, Moderna, and Johnson & Johnson over the alleged infringement of a patent related to gene sequencing technology through their COVID-19 vaccinations.
-
Nokia strikes Hisense license deal as TV maker prefers global patent peace over London dead end; Acer, ASUS lose important co-defendant
Unlike Hisense, Acer and ASUS make computers that are also used for recording video. Encoding claims, however, are outside the ITU FRAND scope.
-
Roku takes HEVC Advance license: court filings in Brazil, UPC; UPDATE: Advance confirms both device and streaming license
A Brazilian court document and a flurry of non-public UPC filings pointed to a settlement, which was subsequently confirmed.
-
Contrasting appellate tactics show Amazon feels protected by UK ASI against InterDigital’s Munich AILI, but is scared of UPC sua sponte sanctions
There are two striking differences between Amazon’s UPC and Munich appeals of InterDigital’s anti-interim-license injunctions.
-
Tesla should learn from Amazon-InterDigital, take an Avanci 5G license: even if its long-shot UKSC appeal succeeded, it wouldn’t help
For cross-jurisdictional reasons, Tesla should give up on its UK case against Avanci and InterDigital, in which it lost the first two rounds.
-
CJEU publishes European Parliament’s suit against European Commission’s decision to withdraw SEP Regulation
The Commission “prematurely” brought the legislative procedure to an end without legitimate grounds supported by cogent evidence and arguments for doing so, the EP has alleged.
-
China’s top court grants Novo Nordisk win over key Ozempic patent
China’s Supreme People’s Court has upheld a lower court’s decision recognizing the validity of Novo Nordisk’s compound patent related to semaglutide, which is found in the company’s blockbuster drugs Ozempic, Wegovy, and Rybelsus.